Expression of t-DARPP Mediates Trastuzumab Resistance in Breast Cancer Cells
Open Access
- 15 July 2008
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 14 (14), 4564-4571
- https://doi.org/10.1158/1078-0432.ccr-08-0121
Abstract
Purpose: We have investigated the role of t-DARPP in trastuzumab resistance in ERBB2-amplified and overexpressed breast cancer cell lines. Experimental Design: We have used the HR-5 and HR-6 trastuzumab-resistant cells that were established from tumors that recurred in the presence of trastuzumab therapy following xenografts of BT-474 cells in nude mice. In addition, SKBR-3 cells, engineered for stable expression of t-DARPP, and HCC-1569 cells, which have constitutive expression of t-DARPP and are de novo resistant to trastuzumab, were used. Results: We reported ≥15-fold up-regulation of mRNA and protein levels of t-DARPP in HR-5 and HR-6 cells compared with their progenitor BT-474 trastuzumab-sensitive cells. The t-DARPP expression was not regulated by changes in its promoter DNA methylation levels. The SKBR-3 cells stably expressing t-DARPP developed resistance to trastuzumab compared with their parental cells and empty vector controls (P < 0.01). The trastuzumab-resistant cell lines showed a significant increase in pAKT (Ser473) and BCL2 protein levels. The small interfering RNA knockdown of t-DARPP in all trastuzumab-resistant cells led to a significant reduction in ERBB2, pAKT (Ser473), and BCL2 protein levels with a significant decrease in cell viability (P ≤ 0.001) and an increase in cleaved caspase-3 levels, indicating the progression of these cells toward apoptosis. The t-DARPP protein was associated with both heat shock protein 90 and ERBB2 forming a potential protein complex. This association may play a role in regulating ERBB2 protein in trastuzumab-resistant cells. Conclusion: We conclude that t-DARPP is a novel molecular target that can mediate the therapeutic resistance to trastuzumab in breast cancer cells.Keywords
This publication has 27 references indexed in Scilit:
- A Functional Genetic Approach Identifies the PI3K Pathway as a Major Determinant of Trastuzumab Resistance in Breast CancerCancer Cell, 2007
- Human Breast Cancer Cells Selected for Resistance to Trastuzumab In vivo Overexpress Epidermal Growth Factor Receptor and ErbB Ligands and Remain Dependent on the ErbB Receptor NetworkClinical Cancer Research, 2007
- A collection of breast cancer cell lines for the study of functionally distinct cancer subtypesCancer Cell, 2006
- Mechanisms of Disease: oncogene addiction—a rationale for molecular targeting in cancer therapyNature Clinical Practice Oncology, 2006
- Molecular Dissection of 17q12 Amplicon in Upper Gastrointestinal AdenocarcinomasMolecular Cancer Research, 2006
- Darpp-32: a Novel Antiapoptotic Gene in Upper Gastrointestinal CarcinomasCancer Research, 2005
- Heat Shock Protein 90 Stabilization of ErbB2 Expression Is Disrupted by ATP Depletion in MyocytesJournal of Biological Chemistry, 2005
- PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patientsCancer Cell, 2004
- HER (erbB) tyrosine kinase inhibitors in the treatment of breast cancerSeminars in Oncology, 2002
- HER2/neu AMPLIFICATION AND COMEDO TYPE BREAST CARCINOMAThe Lancet, 1989